Clearmind Medicine Inc. Common Shares - CMND STOCK NEWS

Welcome to our dedicated page for Clearmind Medicine Common Shares news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine Common Shares stock.

Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics. The company focuses on addressing widespread and under-treated health issues, particularly alcohol use disorder (AUD).

Currently, Clearmind's flagship compound, CMND-100, is in the spotlight. This MEAI-based (5-methoxy-2-aminoindane) formula has shown promising pre-clinical results in disrupting binge drinking behaviors without inducing hallucinations. The Israeli Ministry of Health has recently approved a Phase I/IIa clinical trial for CMND-100, marking a significant milestone in its development.

Clearmind's intellectual property portfolio is robust and growing, comprising eighteen patent families and 27 granted patents. Recent developments include nine new patent applications filed with the USPTO, highlighting compositions for treating alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. These efforts reflect the company's commitment to expanding and protecting its IP assets.

Collaborations play a crucial role in Clearmind's strategy. The company has entered exclusive licensing agreements with institutions such as the Hebrew University of Jerusalem, further enriching its portfolio with generation 3.0 psychedelic compounds aimed at treating addiction and mental health disorders. Additionally, Clearmind has initiated a groundbreaking partnership with Yissum Research Development Company for PTSD treatments.

Another key project is Clearmind's proprietary MEAI-based alcohol substitute beverage program. This ethanol-free alternative aligns with the growing global trend towards no- and low-alcohol consumption, offering a health-focused option for consumers.

Clearmind Medicine Inc. continues to execute its intellectual property and development strategies, positioning itself at the forefront of psychedelic-based medical treatments. The company’s shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under 'CWY0'.

For more information, please visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

12/01/2023 08:14 AM

News

Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial

Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND) announced positive results from its pre-clinical trial in collaboration with SciSparc for its obesity and metabolic disorder program. The trial combined Clearmind's MEAI, a novel proprietary psychedelic treatment, with SciSparc's Palmitoylethanolamide (PEA) to observe their safety and impact on various metabolic and behavioral parameters. Results showed increased metabolic processes, fat oxidation, and reduced appetite, signifying a significant step forward in developing safer and effective therapies for weight management.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

18.29%

Tags

11/28/2023 08:25 AM

News

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment

Rhea-AI Summary

Clearmind Medicine Inc. (CMND) announces positive results from pre-clinical trial for MEAI and PEA combination treatment for obesity and metabolic disorders. The trial showed increased fat oxidation, weight loss, and reduced appetite, indicating potential for safer and more effective weight management therapies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

10.67%

Tags

11/27/2023 08:55 AM

News

Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures

Rhea-AI Summary

Clearmind Medicine Inc. (CMND) to participate in a virtual event with MAPS founder, Rick Doblin, to discuss the growing international psychedelic space and the development of novel psychedelic-derived therapeutics. The event is part of The Psychedelic Association of Canada 'Industry Presents' Series and will be hosted by Gillian Maxwell, a PAC Board Member.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-16.67%

Tags

11/21/2023 08:15 AM

News

Clearmind Medicine Announces 1-for-30 Reverse Share Split

Rhea-AI Summary

Clearmind Medicine Inc. (CMND) announces a 1-for-30 reverse share split to regain compliance with the Nasdaq Minimum Bid Price Rule. The company will have 607,381 Ordinary Shares issued and outstanding after the split. The reverse split was approved by shareholders and will be effective from November 28, 2023. Clearmind is a biotech company focused on developing psychedelic-derived therapeutics for under-treated health problems.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.68%

Tags

11/17/2023 04:15 PM

News

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance

Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) announced that its shareholders approved a reverse stock split to regain compliance with the Nasdaq's Minimum Bid Price Rule. The Company received a Staff Delisting Determination from Nasdaq and plans to appeal the decision. The reverse stock split is expected to be effective soon, with additional details to be announced shortly.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.46%

Tags

11/15/2023 07:37 AM

News

Clearmind Medicine Announces Shareholders Meeting Results

Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND) announces shareholder approval for board matters, equity incentive plan, and share consolidation to advance its biotech initiatives in psychedelic-derived therapeutics.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.79%

Tags

11/09/2023 09:20 AM

News

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Rhea-AI Summary

Clearmind Medicine Inc. (CMND) announces a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University for its Phase I/IIa clinical trial of CMND-100, a potential treatment for Alcohol Use Disorder (AUD). The trial will focus on tolerability, safety, pharmacokinetics, and efficacy in reducing drinking patterns and cravings in individuals with moderate-to-severe AUD.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.54%

Tags

10/05/2023 09:00 AM

News

Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th

Rhea-AI Summary

Clearmind Medicine Inc. to participate in the 8th Annual Dawson James Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.29%

Tags

09/28/2023 09:00 AM

News

Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th

Rhea-AI Summary

Clearmind Medicine Inc. announces participation in LD Micro Main Event XVI Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.62%

Tags

09/19/2023 10:30 AM

News

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)

Rhea-AI Summary

Aegis Capital Corp. served as Exclusive Placement Agent for Clearmind Medicine Inc.'s $2.25 million Public Offering (NASDAQ: CMND).

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of Clearmind Medicine Common Shares (CMND)?

The current stock price of Clearmind Medicine Common Shares (CMND) is $1.72 as of December 24, 2024.

What is the market cap of Clearmind Medicine Common Shares (CMND)?

The market cap of Clearmind Medicine Common Shares (CMND) is approximately 7.5M.

What is Clearmind Medicine Inc.'s primary area of focus?

Clearmind Medicine Inc. focuses on the discovery and development of novel psychedelic-derived therapeutics to address widespread and under-treated health problems, particularly alcohol use disorder (AUD).

What is CMND-100?

CMND-100 is Clearmind's flagship MEAI-based compound aimed at treating alcohol use disorder. It has shown promising pre-clinical results in reducing binge drinking without causing hallucinations.

What recent clinical developments has Clearmind made?

The Israeli Ministry of Health recently approved a Phase I/IIa clinical trial for CMND-100 to treat alcohol use disorder, marking a significant milestone in its development.

What are the key features of Clearmind's intellectual property portfolio?

Clearmind's intellectual property portfolio includes eighteen patent families and 27 granted patents, with recent additions focusing on treatments for alcohol use disorder, cocaine addiction, and obesity-related disorders.

What strategic collaborations has Clearmind entered into?

Clearmind has entered exclusive licensing agreements with the Hebrew University of Jerusalem and Yissum Research Development Company, enriching its portfolio with psychedelic compounds for treating addiction and mental health disorders.

What is Clearmind's MEAI-based alcohol substitute beverage program?

Clearmind is developing a proprietary, ethanol-free MEAI-based alcohol substitute beverage. This product aligns with the growing trend towards no- and low-alcohol consumption and aims to offer a health-focused alternative.

Where are Clearmind's shares traded?

Clearmind's shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under the symbol 'CWY0'.

How can I contact Clearmind Medicine Inc. for more information?

For more information, you can visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

What is Clearmind's approach to intellectual property?

Clearmind is committed to expanding and protecting its intellectual property by filing additional patents and remaining opportunistic regarding the acquisition of new IP assets.